Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$21.52 USD
-0.53 (-2.40%)
Updated May 6, 2024 04:00 PM ET
After-Market: $21.51 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Cassava Sciences, Inc. [SAVA]
Reports for Purchase
Showing records 41 - 60 ( 118 total )
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 2123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Simufilam Open-Label, One-Year Phase 2 Results Point to Cognitive Function Improvement; Reiterate Buy and $124 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 12123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 11123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 1123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 122122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 121122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 12122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Raises $50M, When Cash Balance Sits at Over $174M - Lowering Price Target to $11, Maintain SELL
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 112122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 111122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Revision - We Maintain Our Sell, and $12 Price Target for SAVA
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Simufilam Enrollment Remains on Track Across Alzheimers Disease Studies; Reiterate Buy and $124 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
3Q22 Review: Maintain SELL but Raising Price Target to $12 from $8, as Phase 3 Enrollment Increases
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 11122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 102122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Second Open-Label Study Initiated for Phase 3: Maintain SELL, $8 Price Target
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 101122
Provider: Stock Traders Daily
Analyst: Research Department